ReviewGene therapy2003
Immune responses to replication-defective HSV-1 type vectors within the CNS: implications for gene therapy.
Review in Gene therapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 44 citations in OpenAlex.
- Overcoming the blood-brain barrier in neurodegenerative disorders and brain tumours.IET nanobiotechnology · 2020Review
- Toward Combined Cell and Gene Therapy for Genodermatoses.Cold Spring Harbor perspectives in biology · 2020Review
- Gene delivery with viral vectors for cerebrovascular diseases.Frontiers in bioscience (Elite edition) · 2013Review
- Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications.Pharmaceuticals (Basel, Switzerland) · 2012Article
- Evaluation and optimization of the administration of a selectively replicating herpes simplex viral vector to the brain by convection-enhanced delivery.Cancer gene therapy · 2011Article
- Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.Pharmacological research · 2010Review
- Herpes Virus Amplicon Vectors.Viruses · 2009Article
- A limited innate immune response is induced by a replication-defective herpes simplex virus vector following delivery to the murine central nervous system.Journal of neurovirology · 2009Article
- Effects of herpes simplex virus amplicon transduction on murine dendritic cells.Human gene therapy · 2009Article
- Improved spatial learning in aged rats by genetic activation of protein kinase C in small groups of hippocampal neurons.Hippocampus · 2009Article
- HSV-1 amplicon viral vector-mediated gene transfer to human bone marrow-derived mesenchymal stem cells.Cancer gene therapy · 2008Article
- Augmentation of anti-tumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction.Cancer immunology, immunotherapy : CII · 2008Article
- Neuronal specificity of HSV/sleeping beauty amplicon transduction in utero is driven primarily by tropism and cell type composition.Molecular therapy : the journal of the American Society of Gene Therapy · 2007Article
- Improvement in reproductive parameters in hypogonadal female mice by regulated gene replacement therapy in the central nervous system.Gene therapy · 2007Article
- Review
- Herpes simplex virus 1 (HSV-1) for cancer treatment.Cancer gene therapy · 2006Review
- Long-term inducible expression in striatal neurons from helper virus-free HSV-1 vectors that contain the tetracycline-inducible promoter system.Brain research · 2006Article
- Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery.British journal of cancer · 2005Article
- A realistic chance for gene therapy in the near future.Pediatric nephrology (Berlin, Germany) · 2005Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes simplex virus (HSV) is a naturally occurring double-stranded DNA virus that has been adapted into an efficient vector for in vivo gene transfer. HSV-based vectors exhibit wide tropism, large transgene size capacity, and moderately prolonged transgene expression profiles. Clinical implementation of HSV vector-based gene therapy for prevention and/or amelioration of human diseases eventually will be realized, but inherently this goal presents a series of significant challenges, one of which relates to issues of immune system involvement. Few experimental reports have detailed HSV vector-engendered immune responses and subsequent resolution events primarily within the confines of the central nervous system. Herein, we describe the immunobiology of HSV and its derived vector platforms, thus providing an initiation point from where to propose requisite experimental investigation and potential approaches to prevent and/or counter adverse antivector immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.